Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06966700 · ClinicalTrials.gov registry record · Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 3
Development phase
2,400
Enrollment target
20
Study locations

NCT06966700: Recruiting Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms, sponsored by Merck Sharp & Dohme.

NCT06966700 is a Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 2,400 participants, above the 544-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (341% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06966700, a Phase 3 study of Breast Neoplasms and Triple Negative Breast Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 3
Development phase
2,400 participants
Enrollment target
20
Study locations

Study Summary

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy

Primary Outcome

pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.

Conditions Studied

Breast Neoplasms Triple Negative Breast Neoplasms HR Low-Positive/HER2-Negative Breast Neoplasms

Interventions

  • BIOLOGICAL Sacituzumab tirumotecan
  • BIOLOGICAL Pembrolizumab
  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG Rescue Medication

Study Locations (20)

California

  • Roy and Patricia Disney Family Cancer Center ( Site 0055) - Burbank
  • Providence Medical Foundation ( Site 0080) - Fullerton
  • Hoag Memorial Hospital Presbyterian ( Site 0010) - Newport Beach
  • Helios Clinical Research ( Site 0061) - Whittier

Florida

  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) - Altamonte Springs
  • Florida Cancer Specialists - South ( Site 7004) - Fort Myers
  • Bioresearch Partner ( Site 0072) - Hialeah
  • Florida Cancer Specialists - North ( Site 7002) - St. Petersburg

Arizona

  • Banner MD Anderson Cancer Center ( Site 0066) - Gilbert
  • University of Arizona Cancer Center ( Site 0035) - Tucson

Colorado

  • Intermountain Health Cancer Center Saint Joseph ( Site 0062) - Denver
  • Intermountain Health St. Mary's Regional Hospital ( Site 0054) - Grand Junction

Indiana

  • Fort Wayne Medical Oncology and Hematology ( Site 0084) - Fort Wayne
  • Franciscan Health ( Site 0077) - Indianapolis

Louisiana

  • Ochsner Clinic Foundation ( Site 0021) - New Orleans
  • Louisiana State University Health Sciences Shreveport ( Site 0053) - Shreveport

Missouri

  • Saint Luke's Cancer Institute ( Site 0059) - Kansas City
  • Washington University Siteman Cancer Center ( Site 0031) - St Louis

Maine

  • New England Cancer Specialists ( Site 0051) - Westbrook

Trial Details

FieldValue
Enrollment Target 2,400 participants
Start Date 2025-06-30
Est. Completion 2034-12-29
Phase Phase 3
Merck Sharp & Dohme

558 total trials

What NCT06966700 shows while recruiting

NCT06966700 is an interventional study that assigns participants to a tested intervention. Its 2,400 participants enrollment target places it among the larger protocols in the corpus, above the 544-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (341% higher).

The record links to 3 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.

NCT06966700 names 20 study sites across 9 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06966700 about?

NCT06966700 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)". Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of...

What is the current status of trial NCT06966700?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,400 participants. The study started on 2025-06-30. Estimated completion is 2034-12-29.

What conditions does trial NCT06966700 study?

This clinical trial studies the following conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms.

What interventions are being tested in trial NCT06966700?

The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), Rescue Medication (DRUG).

Who is sponsoring clinical trial NCT06966700?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06966700 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06966700's enrollment target sits among peer trials

2,400 5th of 97 higher than 93 of 97 other Breast Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05185440 · 2,400 participants · NA

    Reducing Alcohol Involved Sexual Violence in Higher Education

  • NCT05285527 · 2,400 participants · NA

    MiSight 1 Day Safety Post-Approval Study

  • NCT05738330 · 2,400 participants · NA

    Symptom Monitoring in Hemodialysis

  • NCT05833360 · 2,400 participants

    Prospective Study of oncRNA Stratification of Cancer by Size and Stage

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06966700

Source: ClinicalTrials.gov NCT06966700, the US trial registry maintained by the National Library of Medicine. NCT06966700 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.